Pushkal Garg Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

ALNY Quotes by TradingView

Pushkal Garg is EVP Chief R&D of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 20,221 shares of ALNY, which is worth approximately $9.2 Million. The most recent transaction as insider was on Aug 19, 2025, when has been sold 1,455 shares (Common Stock) at a price of $458.88 per share, resulting in proceeds of $667,670. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 20.2K
0% 3M change
29.55% 12M change
Total Value Held $9.2 Million

Pushkal Garg Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 19 2025
SELL
Open market or private sale
$667,670 $458.88 p/Share
1,455 Reduced 6.71%
20,221 Common Stock
Aug 18 2025
SELL
Open market or private sale
$631,424 $452.31 p/Share
1,396 Reduced 6.05%
21,676 Common Stock
Aug 15 2025
BUY
Grant, award, or other acquisition
-
2,851 Added 11.0%
23,072 Common Stock
Mar 24 2025
SELL
Open market or private sale
$1,633,500 $300.0 p/Share
5,445 Reduced 21.21%
20,221 Common Stock
Mar 24 2025
BUY
Exercise of conversion of derivative security
$229,887 $42.22 p/Share
5,445 Added 17.5%
25,666 Common Stock
Mar 21 2025
SELL
Open market or private sale
$1,231,485 $285.0 p/Share
4,321 Reduced 17.61%
20,221 Common Stock
Mar 04 2025
SELL
Open market or private sale
$194,824 $241.12 p/Share
808 Reduced 3.19%
24,542 Common Stock
Mar 03 2025
SELL
Open market or private sale
$428,574 $245.04 p/Share
1,749 Reduced 6.45%
25,350 Common Stock
Mar 03 2025
BUY
Grant, award, or other acquisition
-
14,137 Added 34.28%
27,099 Common Stock
Feb 28 2025
SELL
Open market or private sale
$225,054 $240.7 p/Share
935 Reduced 6.73%
12,962 Common Stock
Feb 27 2025
BUY
Exercise of conversion of derivative security
-
1,908 Added 12.07%
13,897 Common Stock
Feb 18 2025
SELL
Open market or private sale
$393,594 $254.26 p/Share
1,548 Reduced 11.44%
11,989 Common Stock
Feb 14 2025
SELL
Open market or private sale
$402,940 $258.13 p/Share
1,561 Reduced 10.34%
13,537 Common Stock
Feb 13 2025
BUY
Grant, award, or other acquisition
-
3,109 Added 17.08%
15,098 Common Stock
Jan 27 2025
SELL
Open market or private sale
$14,988,720 $285.0 p/Share
52,592 Reduced 81.44%
11,989 Common Stock
Jan 27 2025
BUY
Exercise of conversion of derivative security
$4,347,520 $88.95 p/Share
48,876 Added 43.08%
64,581 Common Stock
Dec 12 2024
SELL
Open market or private sale
$440,838 $251.62 p/Share
1,752 Reduced 10.04%
15,705 Common Stock
Nov 26 2024
SELL
Open market or private sale
$421,088 $250.35 p/Share
1,682 Reduced 8.79%
17,457 Common Stock
Nov 25 2024
BUY
Grant, award, or other acquisition
-
3,434 Added 15.21%
19,139 Common Stock
Oct 08 2024
BUY
Grant, award, or other acquisition
-
96 Added 0.61%
15,705 Common Stock
Jun 25 2024
SELL
Open market or private sale
$482,470 $229.42 p/Share
2,103 Reduced 11.87%
15,609 Common Stock
Jun 24 2024
BUY
Grant, award, or other acquisition
-
4,295 Added 19.52%
17,712 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
4,751 Added 26.15%
13,417 Common Stock
Feb 28 2024
SELL
Open market or private sale
$89,744 $156.35 p/Share
574 Reduced 6.21%
8,666 Common Stock
Feb 27 2024
BUY
Exercise of conversion of derivative security
-
1,908 Added 17.12%
9,240 Common Stock

Also insider at

SQZ
SQZ Biotechnologies Co Healthcare
Director
PG

Pushkal Garg

EVP Chief R&D
Cambridge, MA

Track Institutional and Insider Activities on ALNY

Follow ALNYLAM PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ALNY